<div id="readability-page-1"><p><span>USANA Health Sciences (NYSE:USNA - Get Free Report)</span> was upgraded by investment analysts at Zacks Research from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report issued on Tuesday,Zacks.com reports.</p><p>Other equities analysts have also recently issued reports about the company. Wall Street Zen cut USANA Health Sciences from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, October 11th. Weiss Ratings  reiterated a &#34;sell (d+)&#34; rating on shares of USANA Health Sciences in a research report on Monday. Three investment analysts have rated the stock with a Hold rating and one  has given a Sell rating to the company's stock. According to MarketBeat, USANA Health Sciences presently has an average rating of &#34;Reduce&#34; and an average target price of $36.00.</p><div><p><span></span><span>Get <strong>USANA Health Sciences</strong> alerts:</span></p></div><p><b>Read Our Latest Report on USNA</b></p><h2>USANA Health Sciences Stock Performance</h2><p>USNA opened at $20.90 on Tuesday. The company's 50-day simple moving average is $20.80 and its two-hundred day simple moving average is $27.18. The stock has a market capitalization of $382.09 million, a P/E ratio of 23.75, a P/E/G ratio of 0.97 and a beta of 0.66. USANA Health Sciences has a 52-week low of $18.48 and a 52-week high of $38.76. </p><p>USANA Health Sciences (NYSE:USNA - Get Free Report) last released its quarterly earnings data on Thursday, October 9th. The company reported $0.56 earnings per share for the quarter. The firm had revenue of $200.22 million during the quarter. USANA Health Sciences had a net margin of 1.86% and a return on equity of 6.97%. USANA Health Sciences has set its Q3 2025 guidance at -0.150--0.150 EPS.  Research analysts forecast that  USANA Health Sciences will post 2.45 EPS for the current fiscal year. </p><h2>Insider Transactions at USANA Health Sciences</h2><p>In related news, Director Frederic J. Winssinger sold 2,000 shares of the stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $19.21, for a total transaction of $38,420.00. Following the completion of the sale, the director owned 5,986 shares in the company, valued at approximately $114,991.06. This trade represents a 25.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director John Turman Fleming sold 1,750 shares of the business's stock in a transaction that occurred on Friday, October 31st. The stock was sold at an average price of $19.79, for a total value of $34,632.50. Following the completion of the transaction, the director directly owned 4,565 shares in the company, valued at approximately $90,341.35. This represents a 27.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 4,807 shares of company stock worth $95,757. Insiders own  0.63% of the company's stock. </p><h2>Hedge Funds Weigh In On USANA Health Sciences</h2><p>Several hedge funds have recently modified their holdings of USNA. US Bancorp DE increased its position in shares of  USANA Health Sciences by 13.1% during the 1st quarter. US Bancorp DE now owns 4,611 shares of the company's stock valued at $124,000 after purchasing an additional 535 shares during the period.  Creative Planning boosted its stake in  USANA Health Sciences by 3.2% during the second quarter. Creative Planning now owns 20,051 shares of the company's stock valued at $612,000 after buying an additional 613 shares in the last quarter.  Quantbot Technologies LP grew its holdings in  USANA Health Sciences by 19.5% during the second quarter. Quantbot Technologies LP now owns 3,957 shares of the company's stock worth $121,000 after acquiring an additional 646 shares during the period.  PNC Financial Services Group Inc. grew its holdings in  USANA Health Sciences by 339.6% during the first quarter. PNC Financial Services Group Inc. now owns 998 shares of the company's stock worth $27,000 after acquiring an additional 771 shares during the period.  Finally, Martingale Asset Management L P raised its position in  USANA Health Sciences by 5.4% in the first quarter. Martingale Asset Management L P now owns 17,542 shares of the company's stock worth $473,000 after acquiring an additional 900 shares in the last quarter. Hedge funds and other institutional investors own  54.25% of the company's stock. </p><h2>About USANA Health Sciences</h2> (Get Free Report)<p>USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.</p><h2>Read More</h2><ul><li>Five stocks we like better than USANA Health Sciences</li><li>What is the S&amp;P/TSX Index?</li><li>Market Momentum: 3 Stocks Poised for Major Breakouts</li><li>How Investors Can Find the Best Cheap Dividend Stocks</li><li>3 Reasons Casey’s General Stores Will Continue Trending Higher</li><li>Value Investing: Is it a Good Strategy in 2022? <span>Hint: Always<span></span></span></li><li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in USANA Health Sciences Right Now?</h2><p>Before you consider USANA Health Sciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.</p><p>While USANA Health Sciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

USNA

<p>Zacks Research upgraded USANA Health Sciences (NYSE:USNA) from a "strong sell" to "hold" rating. Other analysts have issued mixed ratings, with Wall Street Zen downgrading to "hold" and Weiss Ratings maintaining a "sell". The stock opened at $20.90, with a market cap of $382.09 million. Recent insider transactions include sales by directors Frederic J. Winssinger and John Turman Fleming. Hedge funds have adjusted their holdings, with institutional investors owning 54.25% of the stock.</p>

USANA Health Sciences (NYSE:USNA) Upgraded at Zacks Research